This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Malignant neoplasm of liver and intrahepatic bile ducts (controls excluding all cancers)
C3_LIVER_INTRAHEPATIC3_BILE_DUCTS_EXALLC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
individuals
Apply sex-specific rule None
Check conditions None
Check pre-conditions, main-only, mode, registry filters
Cancer registry: Topography ICD-O-3
C22
Cancer registry: Morphology ICD-O-3
ANY
Cancer registry: Behaviour codes
ANY
1 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints None
-
Remove individuals based on genotype QC
689
C3_LIVER_INTRAHEPATIC3_BILE_DUCTS_EXALLC
Control definitions
Control exclude
C3_CANCER, C3_CANCER_WIDE
Extra metadata
First used in FinnGen datafreeze
DF2
No upset plot: script not run.
No upset table: script not run.
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of liver and intrahepatic bile ducts (controls excluding all cancers)
based on the number of shared cases.
Broader endpoints:
- Malignant neoplasm of liver and intrahepatic bile ducts (controls excluding all cancers)
- Malignant neoplasm of liver and intrahepatic bile ducts
- Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder
- Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder (controls excluding all cancers)
- Malignant neoplasm of digestive organs
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 689 | 120 | 569 |
| Unadjusted prevalence (%) | 0.17 | 0.05 | 0.31 |
| Mean age at first event (years) | 70.74 | 67.95 | 71.33 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: C3_LIVER_INTRAHEPATIC3_BILE_DUCTS_EXALLC – Malignant neoplasm of liver and intrahepatic bile ducts (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Malignant neoplasm of liver and intrahepatic bile ducts (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.